TAEUS Clinical Trial to Serve as ENDRA’s Gateway to Asia’s Largest Healthcare Market

ANN ARBOR, Mich. , January 24, 2022–(BUSINESS WIRE)–ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer in enhanced ultrasound technologies, announced that it has obtained approval from the Chinese government’s institutional review of Shanghai First People’s Hospital Affiliated with Shanghai Jiao Tong University, for the first clinical examination of ENDRA’s thermoacoustic enhanced ultrasound (TAEUS®) device to compare nonalcoholic fatty liver disease (NAFLD) in this market.

“ENDRA is revered for bringing our TAEUS® generation to China through one of the country’s most prestigious fitness facilities, Shanghai General,” said François Michelon, President and CEO of Endra. “This partnership is a transparent validation of ENDRA’s generation and provides a vital gateway strategy to the Chinese physical care market, which aims to provide cost-effective physical care to 1400 million citizens, totaling approximately 350 million people affected by NAFLD-NASH. The generation of TAEUS® points of care aligns very well with China’s purpose of moving fitness delivery from urban centers to network clinics. “

Shanghai General Hospital is classified as a level 3A center, the highest point of China’s 9-level fitness services classification system, and also has an A rating through China’s National Health Commission, which is awarded to only 12 of the estimated 35,000 fitness services in China. Shanghai General Hospital provides the highest quality care to approximately four million inpatients and outpatients annually in a variety of clinical specialties.

This is ENDRA’s first clinical trial partnership in Asia and the eighth in the world. The collaboration will contribute to the clinical evidence of the TAEUS ultrasound device® in NAFLD patients in China and will be a reference site for the commercialization of TAEUS® in the world’s most populous market. In anticipation of the advent of the TAEUS® platform in China, ENDRA has created a strong intellectual property portfolio with 8 patents granted to date in China.

It is expected to start in 2022 and will be led by Professor Lu Lungen, Vice President of the Chinese Society of Hepatology, Head of the Department of Gastroenterology at Shanghai General Hospital, and Professor Shen Hua, Head of the Shanghai International Healthcare Center. General Hospital.

“We are committed to maintaining a modern, first-class, research-driven hospital that provides low-cost, high-efficiency clinical care. We look to the future, to the TAEUS generation® of ENDRA with our NAFLD patients as a promising option for more invasive treatments or beloved technical care,” said Professor Lungen.

The objectives of the study are to compare the TAEUS liver device® with a reference measurement of liver fats, based on what we decided through the existing PDFF-MRI (proton density fat fraction through magnetic resonance imaging) reference in 75 patients. also provide ENDRA with ongoing clinical feedback on the design and clinical performance of the product.

TAEUS® is lately legal for sale in countries that recognize CE marking, adding those of the European Union, and a 510(k) application has been filed with the U. S. Food and Drug Administration. USA

About Shanghai First People Hospital affiliated with Shanghai Jiao Tong University Shanghai General Hospital was founded in 1864 by French consuls as one of the largest and oldest Western medical hospitals in China. Circles. For 25 consecutive years, Shanghai General Hospital has been awarded as a civilized style unit through the Shanghai Municipal Government. As a Class A tertiary general hospital, Shanghai General operates 4 local hospitals and maintains close collaborative relationships with other public hospitals in the surrounding provinces. For more information, make a stop at www. shgh. cn (https://eng. shgh. cn).

About ENDRA Life Sciences Inc. ENDRA Life Sciences is a pioneer in enhanced thermoacoustic ultrasound (TAEUS®), a revolutionary generation in progression to visualize tissues as MRI, but at 1/50 of the load and at the point of patient care. TAEUS® is designed to work in concert with 400,000 wheeled ultrasound scanners recently used around the world. TAEUS® focused first of all on measuring fats in the liver as a means of assessing and tracking non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), chronic liver conditions that affect more than one billion people worldwide and for which no practical diagnostic tools exist. Beyond the liver, ENDRA is exploring several other TAEUS clinical programs®, adding tissue temperature visualization during electrical surgeries. For more information, make a stopover in www. endrainc. com.

Forward-Looking Statements Any statements in this release that are not based on past facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. based on safe assumptions and describe our long-term plans, methods and expectations, they can sometimes be known by the use of forward-looking terms such as “believe”, “expect”, “may”, “will”, “should”, “can” simply “, “seek”, “intend”, “plan”, “target”, “estimate”, “anticipate” or other comparable terms. Examples of forward-looking statements include, but are not limited to, estimates of the timing of long-term events and achievements, such as expectations regarding long-term milestones and sales, our 510(k) filing with the FDA, and the commercialization of the TAEUS® device. ; and expectations regarding ENDRA’s business strategy. Forward-looking statements involve inherent dangers and uncertainties that may cause actual effects to differ materially from those contained in forward-looking statements, due to a variety of factors, including our ability to expand commercially feasible technology; receipt of mandatory regulatory approvals; the effect of COVID-19 on our business plans; our ability to locate and retain progression partners, the market acceptance of our technology, the extent and nature of the festival in our industry; our ability to protect our intellectual property; and other dangers and uncertainties described in ENDRA’s filings with the Securities and Exchange Commission. The forward-looking statements made in this release speak only as of the date of this release, and ENDRA assumes no legal responsibility to update such forward-looking statements to reflect actual effects or adjustments in expectations, unless required by law. ask for the opposite.

See the businesswire. com edition: https://www. businesswire. com/news/home/20220124005067/en/

Contacts

Company Contact: Irina PestrikovaSepte Director, Financeinvestors@endrainc. com www. endrainc. com Investor Relations Contact: Yvonne BriggsLHA Investor Relations(310) 691-7100ybriggs@lhai. com